Direct detection of cervical carcinogenesis through mRNA

Emerging Issues on HPV Infections: From Science to Practice

Volumn , Issue , 2006, Pages 82-102

  Skomedal, H ^a,b   Kraus, I ^a   Silva, I ^b   Molden, T ^a   Hovland, S ^b   Morland, G ^b   Morland, E ^b   Karlsen, F ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NorChip AS   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45349106757     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000092740     Document Type: Chapter

References (48)

1. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141: 680-689.
2. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P. HPV testing in primary screening of older women. Br J Cancer 1999;81:554-558.
3. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-951.
4. Ngelangel CA, Limson GM, Cordero CP, Abelardo AD, Avila JM, Festin MR. Acetic-acid guided visual inspection vs cytology-based screening for cervical cancer in the Philippines. Int J Gynaecol Obstet 2003;83:141-150.
5. Rodriguez-Reyes ER, Cerda-Flores RM, Quinonez-Perez JM, Velasco-Rodriguez V, Cortes-Gutierrez EI. Acetic acid test: a promising screening test for early detection of cervical cancer. Anal Quant Cytol Histol 2002;24:134-136.
6. Cronje HS, Parham GP, Cooreman BF, de Beer A, Divall P, Bam RH. A comparison of four screening methods for cervical neoplasia in a developing country. Am J Obstet Gynecol 2003;188: 395-400.
7. Denny L, Kuhn L, Pollack A, Wright TC Jr. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer 2002;94:1699-1707.
8. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, Onsrud M, Thoresen S. DNAversus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005;97:908-915.
9. Gregoire L, Arella M, Campione-Piccardo J, Lancaster WD. Amplification of human papillomavirus DNA sequences by using conserved primers. J Clin Microbiol 1989;27:2660-2665.
10. Gravitt PE, Manos MM. Polymerase chain reaction-based methods for the detection of human papillomavirus DNA. IARC Sci Publ 1992;121-133.
11. Snijders PJ, Schulten EA, Mullink H, ten Kate RW, Jiwa M, van der Waal I, Meijer CJ, Walboomers JM. Detection of human papillomavirus and Epstein-Barr virus DNA sequences in oral mucosa of HIV-infected patients by the polymerase chain reaction. Am J Pathol 1990;137: 659-666.
12. Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, To KF, Wong YF, Cheung JL, Chan DP, Hui M, Ip M. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 2006;118:243-245.
13. Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Costa S, Benedetto A, Casolati EA, Favalli C, Paba P, Di Bonito P, Mariani L, Syrjänen S, Bonifacio D, Accardi L, Zanconati F, Syrjänen K. Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. Am J Clin Pathol 2005;124:113-121.
14. Gulliksen A, Solli LA, Drese KS, Sorensen O, Karlsen F, Rogne H, Hovig E, Sirevag R. Parallel nanoliter detection of cancer markers using polymer microchips. Lab Chip 2005;5:416-420.
15. Ozbun MA, Meyers C. Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b. J Virol 1997;71:5161-5172.
16. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-698.
17. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12: 2061-2072.
18. Um SJ, Rhyu JW, Kim EJ, Jeon KC, Hwang ES, Park JS. Abrogation of IRF-1 response by highrisk HPV E7 protein in vivo. Cancer Lett 2002;179:205-212.
19. Iftner T, Oft M, Bohm S, Wilczynski SP, Pfister H. Transcription of the E6 and E7 genes of human papillomavirus type 6 in anogenital condylomata is restricted to undifferentiated cell layers of the epithelium. J Virol 1992;66:4639-4646.
20. Smotkin D, Prokoph H, Wettstein FO. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J Virol 1989;63:1441-1447.
21. Stacey SN, Jordan D, Snijders PJ, Mackett M, Walboomers JM, Arrand JR. Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J Virol 1995;69:7023-7031.
22. Shally M, Alloul N, Jackman A, Muller M, Gissmann L, Sherman L. The E6 variant proteins E6IE6IV of human papillomavirus 16: expression in cell free systems and bacteria and study of their interaction with p53. Virus Res 1996;42:81-96.
23. Guccione E, Pim D, Banks L. HPV-18 E6I modulates HPV-18 full-length E6 functions in a cell cycle dependent manner. Int J Cancer 2004;110:928-933.
24. Pim D, Massimi P, Banks L. Alternatively spliced HPV-18 E6 protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 1997;15:257-264.
25. Pim D, Banks L. HPV-18 E6I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 1999;18:7403-7408.
26. Inoue T, Kyo S, Kiyono T, Ishibashi M, Ishiwatari H, Hwang YI, Yutsudo M, Hakura A. Correlation between tumorigenicity and expression levels or splicing patterns of transcripts of the human papillomavirus type 16 E6 gene. Jpn J Cancer Res 1994;85:357-363.
27. Rose BR, Thompson CH, Tattersall MH, Elliott PM, Dalrymple C, Cossart YE. Identification of E6/E7 transcription patterns in HPV 16-positive cervical cancers using the reverse transcription/ polymerase chain reaction. Gynecol Oncol 1995;56:239-244.
28. Kievits T, van Gemen B, van Strijp D, Schukkink R, Dircks M, Adriaanse H, Malek L, Sooknanan R, Lens P. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991;35:273-286.
29. Tyagi S, Kramer FR. Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 1996;14:303-308.
30. Stryer L. Fluorescence energy transfer as a spectroscopic ruler. Annu Rev Biochem 1978;47:819-846.
31. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
32. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-1164.
33. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-998.
34. Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer 2004;90:1407-1413.
35. Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, Rodriguez AC, Bratti MC, Wheeler CM, Burk RD. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005;97:147-150.
36. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-787.
37. Massad LS, Collins YC, Meyer PM. Biopsy correlates of abnormal cervical cytology classified using the Bethesda system. Gynecol Oncol 2001;82:516-522.
38. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-44.
39. Salmeron J, Lazcano-Ponce E, Lorincz A, Hernandez M, Hernandez P, Leyva A, Uribe M, Manzanares H, Antunez A, Carmona E, Ronnett BM, Sherman ME, Bishai D, Ferris D, Flores Y, Yunes E, Shah KV. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 2003;14:505-512.
40. Nakagawa S, Yoshikawa H, Yasugi T, Kimura M, Kawana K, Matsumoto K, Yamada M, Onda T, Taketani Y. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J Med Virol 2000;62:251-258.
41. Crum CP, Genest DR, Krane JF, Hogan C, Sun D, Bellerose B, Kostopoulou E, Lee KR. Subclassifying atypical squamous cells in Thin-Prep cervical cytology correlates with detection of high-risk human papillomavirus DNA. Am J Clin Pathol 1999;112:384-390.
42. Meijer CJ, Helmerhorst TJ, Rozendaal L, van der Linden JC, Voorhorst FJ, Walboomers JM. HPV typing and testing in gynaecological pathology: has the time come? Histopathology 1998;33: 83-86.
43. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women _30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005;14:367-372.
44. Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, Skare GB, Skomedal H, Thoresen SO, Hagmar B. Predicting CIN2_ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005;114:973-976.
45. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J Med Virol 2004;73: 65-70.
46. Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Rong SD, Huang MN, Zhao FH, Wu LY, Ren SD, Huang RD, Washington MF, Pan QJ, Li L, Fife D. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer 2003;13:819-826.
47. Petry KU, Menton S, Menton M, Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-1577.
48. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-738.